Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    DFV890
Previous Study | Return to List | Next Study

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04382053
Recruitment Status : Recruiting
First Posted : May 11, 2020
Last Update Posted : September 22, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The study will assess the efficacy and safety of DFV890 for the treatment of SARS-Cov-2 infected patients with COVID-19 pneumonia and impaired respiratory function.

Condition or disease Intervention/treatment Phase
COVID 19 Pneumonia, Impaired Respiratory Function Drug: DFV890 Drug: Standard of Care (SoC) Phase 2

Detailed Description:

This is a Phase 2, randomized, controlled, open label multi-center study to assess the efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function.

The study consists of four parts:

Screening / Baseline visit (Day -1 to 1): lasts up to a maximum of 24 hours and comprises a screening / baseline assessment. This visit will be used to confirm that the study inclusion and exclusion criteria are met and serves as baseline assessment prior to randomization.

Treatment period (Day 1-15): Participants in the investigational treatment arm will receive DFV890 orally or via a nasogastric feeding tube administered for a total of 14 days in addition to SoC. Study drug will be supplied in tablet form which can be crushed, allowing for both oral and nasogastric administration. Participants in the control arm will receive SoC alone.

Participants will be randomized as soon as possible, but within a maximum of 24 hours after screening in a 1:1 ratio to receive either DFV890 in addition to SoC or SoC alone. Study assessments will be conducted every 2 days for hospitalized participants.

The End of Treatment (EOT) visit will take place on Day 15. If participants are discharged from the hospital prior to Day 15, assessments on the day of discharge should be performed according to the schedule listed under Day 15; participants will continue to take the investigational treatment at home to complete the 14-day treatment period and the participants should return to the site for the Day 15/EOT assessment (all other visits between discharge and Day 15 can be omitted). If a hospital visit is not possible at Day 15, then home nursing services may be used to support this last visit where these are available in accordance with local guidelines and should include all possible assessments (e.g., oxygen saturation with portable monitors).

Follow-up (Day 16-29): After completion of the 14 day- treatment period, participants will be observed until Day 29 or discharged from hospital, whichever is sooner. Study assessments to be conducted every 2 days for hospitalized participants.

If participants are discharged from hospital prior to Day 29, a study visit conducted by telephone will occur on Day 29 (all other visits between discharge and Day 29 can be omitted).

30-day safety follow-up assessment (Day 45): A follow-up visit for safety will be conducted by telephone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function
Actual Study Start Date : May 27, 2020
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: DFV890 + SoC
DFV890 will be administered for 14 days in addition to Standard of Care (SoC). SoC will be used as an active comparator.
Drug: DFV890
DFV890 administerated in addition to the SoC for 14 days

Drug: Standard of Care (SoC)
SoC includes a variety of supportive therapies that ranges from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral agents and intravenous corticosteroids.

Active Comparator: Standard of Care (SoC)
Standard of Care will be used as a comparator arm.
Drug: Standard of Care (SoC)
SoC includes a variety of supportive therapies that ranges from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral agents and intravenous corticosteroids.




Primary Outcome Measures :
  1. APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier) [ Time Frame: up to Day 15 ]
    The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. Worst case imputation for death will be applied.


Secondary Outcome Measures :
  1. Serum C-reactive protein (CRP) levels [ Time Frame: up to Day 29 ]
    C-reactive protein (CRP) is a blood test marker for inflammation in the body. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). It will be analyzed on a log-scale fitting a repeated measures mixed model including treatment group, study day, the three stratification factors and log transformed baseline CRP as a covariate.

  2. Clinical status over time [ Time Frame: up to Day 29 ]
    Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.

  3. Proportion of participants not requiring mechanical ventilation for survival. [ Time Frame: Day 15, Day 29 ]
    Proportion of participants not requiring mechanical ventilation for survival.

  4. Proportion of participants with at least one-point improvement from baseline in clinical status [ Time Frame: Baseline, Day 15, Day 29 ]
    Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male and female patients aged 18-80 years inclusive at screening
  • Clinically diagnosed with the SARS-CoV-2 virus by polymerase chain reaction (PCR) or by other approved diagnostic methodology within 7 days prior to randomization
  • Hospitalized with COVID-19-induced pneumonia evidenced by chest X-ray, computed tomography scan (CT scan) or magnetic resonance scan (MR scan), taken within 5 days prior to randomization (within 24 hours in patients in the Netherlands)
  • Impaired respiratory function, defined as peripheral oxygen saturation (SpO2) ≤93% on room air or partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) <300 millimeter of mercury (mmHg) at screening. For cities located at altitudes greater than 2500 m above sea level, these will be substituted with SpO2 <90% and PaO2/FiO2 <250 mmHg.
  • APACHE II score of ≥10 at screening
  • C-reactive protein (CRP) ≥20 mg/L and/or ferritin level ≥600 μg/L at screening
  • Body mass index of ≥18 to <40kg/m2 at screening

Exclusion Criteria

  • Suspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral, or other infection (besides SARS-CoV-2)
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment
  • Intubated prior to randomization
  • Previous treatment with anti-rejection and immunomodulatory drugs within the past 2 weeks, or within the past 30 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies or prohibited drugs, with the exception of hydroxychloroquine, chloroquine or corticosteroids:

For COVID-19 infection, ongoing corticosteroid treatment is permitted at doses as per local SoC For non-COVID-19 disorders, ongoing corticosteroid treatment is permitted at doses up to and including prednisolone 10 mg daily or equivalent In patients in the Netherlands only, the use of hydroxychloroquine and/or chloroquine in the past 2 weeks are exclusionary

  • Serum alanine transaminase (ALT) or aspartate transaminase (AST) >5 times upper limit of normal detected within 24 hours at screening or at baseline (according to local laboratory reference ranges) or other evidence if severe hepatic impairment (Child-Pugh Class C)
  • Absolute peripheral blood neutrophil count of ≤1000/mm3
  • Estimated GFR (eGFR) ≤30 mL/min/1.73m2 (based on CKD-EPI formula)
  • Patients currently being treated with drugs known to be strong or moderate inducers of isoenzyme CYP2C9 and/or strong inhibitors of CYP2C9 and/or strong inducers of cytochrome P450, family 3, subfamily A (CYP3A) and the treatment cannot be discontinued or switched to a different medication prior to starting study treatment
  • Patients with innate or acquired immunodeficiencies
  • Patients who have undergone solid organ or stem cell transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04382053


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Locations
Layout table for location information
Brazil
Novartis Investigative Site Recruiting
Santo Andre, SP, Brazil, 09090-790
Novartis Investigative Site Recruiting
Sao Jose do Rio Preto, SP, Brazil, 15090 000
Novartis Investigative Site Recruiting
Sao Paulo, SP, Brazil, 01327 001
Denmark
Novartis Investigative Site Recruiting
Copenhagen, Denmark, DK-2400
Novartis Investigative Site Recruiting
Hvidovre, Denmark, 2650
Germany
Novartis Investigative Site Recruiting
Heidelberg, Baden-Württemberg, Germany, 69126
Novartis Investigative Site Recruiting
Regensburg, Bavaria, Germany, 93053
Novartis Investigative Site Recruiting
Bonn, Germany, 53105
Novartis Investigative Site Recruiting
Hannover, Germany, 30625
Novartis Investigative Site Recruiting
Wuerzburg, Germany, 97080
Hungary
Novartis Investigative Site Recruiting
Budapest, Hungary, 1121
Novartis Investigative Site Recruiting
Budapest, Hungary, H-1097
Netherlands
Novartis Investigative Site Recruiting
Harderwijk, Netherlands, 3840 AC
Russian Federation
Novartis Investigative Site Recruiting
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site Recruiting
Ekaterinburg, Russian Federation, 620035
Novartis Investigative Site Recruiting
Krasnoyarsk, Russian Federation, 660049
Novartis Investigative Site Recruiting
Saint Petersburg, Russian Federation, 193079
Novartis Investigative Site Recruiting
St-Petersburg, Russian Federation, 199106
South Africa
Novartis Investigative Site Recruiting
George, Western Cape, South Africa, 6529
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7531
Spain
Novartis Investigative Site Recruiting
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site Recruiting
Madrid, Spain, 28006
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04382053    
Other Study ID Numbers: CDFV890D12201
2020-001870-32 ( EudraCT Number )
First Posted: May 11, 2020    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
COVID-19 pneumonia
SARS-CoV-2
APACHE II
DFV890
inflammasome
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Respiratory Insufficiency
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Respiration Disorders